A response to strategy #2: streamlining the regulatory process.
Regulatory burden has contributed to the decline in the production of vaccines in the United States. Production of influenza virus vaccine is perilously limited at a critical period when vulnerable populations are increasing and the threat of a pandemic is looming. Regulatory bodies must work with manufacturers to facilitate implementation of new production practices, to ensure steady expansion of the supply of safe and effective vaccines.
Glezen
W Paul
WP
Influenza Research Center, Department of Molecular Virology, Baylor College of Medicine, Houston, TX 77030, USA. wglezen@bcm.tmc.edu
D004335:Drug and Narcotic Control; D006801:Humans; D007114:Immunization / Q000331:legislation & jurisprudence*; D014481:United States; D014486:United States Food and Drug Administration; D014612:Vaccines / Q000008:administration & dosage / Q000009:adverse effects / Q000600:supply & distribution*
D014612:Vaccines